Alzinova AB (publ)

https://www.alzinova.com

Alzinova AB is a Swedish clinical-stage biopharma company specializing in the treatment of Alzheimer’s disease targeting toxic amyloid beta oligomers. The lead candidate, ALZ-101, is being developed as a therapeutic vaccine for the treatment of Alzheimer's. Alzinova’s proprietary AßCC peptide™ technology enables the development of disease-modifying treatments that target the toxic amyloid beta oligomers involved in the onset and progression of the disease with high precision. Alzheimer’s is one of the most common and devastating neurological diseases globally, with of the order of 40 million people afflicted today. In addition, the antibody ALZ-201 is in preclinical development, and the ambition is to expand the pipeline further. The company’s Certified Adviser on Nasdaq First North Growth Market is Redeye AB. *

	Start	2011-01-01 established
	Industry	Alzheimer drug
	Industry 2	ALZ-101 (Alzinova)
	Person	Torfgård, Kristina (Alzinova 202301 CEO)
	Person 2	Hansson, Sebastian (Alzinova– 202301 Business Development Director before SWIPP)

	Region	Göteborg (Gothenburg)
	Country	Sweden
	Street	11A Erik Dahlbergsgatan
	City	41126 Göteborg
		Address record changed: 2020-12-02

Basic data	Employees	n. a.

		* Document for »About Section«: Alzinova AB. (1/24/23). "Press Release: Alzinova Recruits Business Development Director".

		Record changed: 2025-03-16

Picture EBD Group World of Partnering Opportunities 650x200px

More documents for Alzinova AB (publ)

[1] Alzinova AB. (1/24/23). "Press Release: Alzinova Recruits Business Development Director"....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)